BIO-TECHNE TO PRESENT AT NEUROSCIENCE 2024-THE SOCIETY FOR NEUROSCIENCE (SfN) ANNUAL MEETING

Rhea-AI Summary

Bio-Techne (NASDAQ: TECH) will showcase its neuroscience research solutions at Neuroscience 2024, the Society for Neuroscience (SfN) annual meeting, from October 5-9, 2024, in Chicago. The company will present its portfolio of life science reagents, immunoassays, automated proteomic instruments, and multiomics solutions at booth #1165.

Key highlights include:

• A nanosymposium on brain senescence using the RNAscope™ Multiomic LS assay
• A poster on antibody validation for the COMET™ spatial biology platform
• A Product Theater presentation with FUJIFILM Cellular Dynamics on Alzheimer's disease intracellular signaling using Simple Western™ technology
• Multiple poster presentations on topics such as pTau217 quantification, synaptic research, interneuron heterogeneity, and glioblastoma biomarker evaluation

Bio-Techne's CEO, Kim Kelderman, emphasized the company's commitment to advancing neuroscience research and enabling next-generation therapies.

MINNEAPOLIS, Sept. 24, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its portfolio of solutions advancing neuroscience research at the upcoming annual meeting of the Society for Neuroscience (SfN) at Neuroscience 2024, taking place October 5-9, 2024, in Chicago, Illinois.

At booth #1165, Bio-Techne will feature its market-leading portfolio of high-quality life science reagents, immunoassays, automated proteomic analytical instruments, and multiomics solutions. These technologies are accelerating research by streamlining biomarker discovery and quantification, optimizing neural cell cultures and organoid models, and transforming drug discovery and screening processes.

In a nanosymposium, Bio-Techne will discuss a study investigating senescence in the aging brain, highlighting the novel RNAscope™ Multiomic LS assay for high-throughput spatial analysis. Additionally, the team will present a poster detailing Bio-Techne's commitment to antibody validation for use on COMET^TM, the fully automated, high-throughput, hyperplex spatial biology platform from Lunaphore^TM, a Bio-Techne brand.

Bio-Techne will also host a Product Theater presentation in collaboration with FUJIFILM Cellular Dynamics, Inc. The presentation will focus on intracellular signaling in Alzheimer's disease, including the use of Simple Western™ automated western technology for protein size characterization and quantification directly in complex samples like cell and tissue lysates. This technology will be further highlighted in a poster presentation from Cell Signaling Technology, demonstrating its use in characterizing iPSC-derived microglial activation.

"We are proud to support the advancement of neuroscience research with our portfolio of innovative proteomic research tools, research reagents, and spatial biology solutions," said Kim Kelderman, Bio-Techne's President and Chief Executive Officer. "Scientists rely on our suite of cutting-edge solutions to further the understanding of neuroscience and other biological processes, enabling the development of next-generation therapies and treatments. We are looking forward to showcasing our solutions at this important conference."

To learn more about Bio-Techne's activities at Neuroscience 2024, visit https://www.bio-techne.com/about/events/SfN.

Bio-Techne Speaker Presentations: 

Simple Western™ Capillary Immunoassays: A Game Changer in Elucidating Intracellular Signaling in Alzheimer's Disease
Monday, October 7 at 2:30pm
Presenters: Scott Schachtele, PhD, Product Manager, Neuroscience, FUJIFILM Cellular Dynamics
Charles Haitjema, Senior Research Area Manager, Analytical Solutions Division, Bio-Techne
Location: Exhibit Hall, Aisle 900, Product Theater 1

Investigating Hallmarks of Senescence in the Aging Brain Using a Novel RNA-Protein Multiomic Co-Detection Assay
Wednesday, October 9, 3:00pm - 3:15pm 
Presenter: Debia Wakhloo, PhD, Application Scientist, Marketing
Location: MCP Room S106

Bio-Techne Poster Presentations: An Automated Assay for Precise and Sensitive Quantification of pTau217 in Plasma and Cerebrospinal Fluid
Sunday, October 6, 3:00pm – 4:00pm
Presenter: Yoav Noam, PhD, Senior Manager, Research & Development
Poster Session: LBA003 – Theme C, Late Breaking Posters
Abstract: 13849 

Bridging the Gap in Synaptic Research: Visualizing Neurexin and Neuroligin Interactions Using Multiomic RNAscope Technology
Sunday, October 6, 1:00pm – 2:00pm
Presenter:  Debia Wakhloo, PhD, Application Scientist, Marketing
Poster Session: PSTR143 – Biochemical and Molecular Technologies I
Abstract: 5821

Spatial Multiomic Assay for Studying Interneuron Heterogeneity in the Brain
Tuesday, October 8, 3:00pm – 4:00pm
Presenter:  Anushka Dikshit, PhD, Senior Manager, Applications
Poster Session: LBA009 – Theme I, Late Breaking Posters
Abstract:  13972

Evaluation of IDH1, EGFR, IGF1R and Ki67 Biomarkers in Glioblastoma using Lunaphore COMET™ Platform
Wednesday, October 9, 2:00pm - 3:00pm
Presenter: Alexander Kalyuzhny, PhD, Sr. Manager, Antibody Validation
Poster Session: PSTR444 - Glioblastoma and Other Nervous System Cancers: Mechanisms and Techniques
Abstract: 10867

Poster Presentation, In Collaboration:

Characterization of iPSC-Derived Human Microglial Activation Using Automated, Multiplex Capillary Western Blot Analysis
Sunday, October 6, 10:00am - 11:00am
Presenter: Richard Cho, PhD, Associate Director, Neuroscience, Cell Signaling Technology
Poster Session: PSTR058 - In Vitro Modeling of Neuroinflammation and Neurodegeneration
Abstract: 8455

About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit http://www.bio-techne.com or follow the Company on social media at Facebook, LinkedIn, Twitter or YouTube.

About Bio-Techne Corporation (NASDAQ: TECH)
Contact: David Clair, Vice President, Investor Relations & Corporate Development
david.clair@bio-techne.com 
612-656-4416

View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-to-present-at-neuroscience-2024the-society-for-neuroscience-sfn-annual-meeting-302244769.html

SOURCE Bio-Techne Corporation

FAQ

What will Bio-Techne (TECH) showcase at Neuroscience 2024?

Bio-Techne (TECH) will showcase its portfolio of life science reagents, immunoassays, automated proteomic instruments, and multiomics solutions for neuroscience research at Neuroscience 2024, held from October 5-9, 2024, in Chicago.

What new technology will Bio-Techne (TECH) present at SfN 2024?

Bio-Techne (TECH) will present the RNAscope™ Multiomic LS assay for high-throughput spatial analysis and discuss the COMET™ spatial biology platform from Lunaphore™ at SfN 2024.

What is the focus of Bio-Techne's (TECH) Product Theater presentation at Neuroscience 2024?

Bio-Techne's (TECH) Product Theater presentation at Neuroscience 2024 will focus on intracellular signaling in Alzheimer's disease, featuring the Simple Western™ automated western technology for protein analysis.

Which Bio-Techne (TECH) technologies will be highlighted in poster presentations at SfN 2024?

Poster presentations at SfN 2024 will highlight Bio-Techne's (TECH) technologies including Simple Western™ for microglial activation analysis, RNAscope for synaptic research, and the COMET™ platform for glioblastoma biomarker evaluation.